Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Cannabidiol (CBD), a non-psychoactive compound found in the Cannabis sativa plant, has garnered interest as a potential adjunct therapy for symptoms associated with Multiple Sclerosis (MS), particularly spasticity and pain. The use of CBD for MS is supported by some scientific evidence, though it is not robust and remains somewhat preliminary. The most notable validation comes from clinical studies on nabiximols (Sativex), an oromucosal spray containing a 1:1 ratio of THC and CBD, which has been approved in several countries for the treatment of MS-related spasticity. Randomized controlled trials involving Sativex have shown moderate benefits in reducing spasticity and improving patient-reported outcomes. However, it is important to note that these studies assess a combination of THC and CBD, not CBD alone. Pure CBD has been less extensively studied in MS. A few small studies and preclinical research suggest that CBD may have anti-inflammatory, neuroprotective, and immunomodulatory effects relevant to MS pathology, but clinical trials specifically evaluating CBD alone for MS symptoms are limited. Therefore, while there is some scientific rationale and limited clinical evidence for the use of cannabidiol (especially in combination with THC) in managing certain MS symptoms, the overall strength of evidence is modest, and more rigorous studies are needed to clarify its efficacy and safety profile in this context.

More about Cannabidiol
More about Multiple Sclerosis

Other ingredients used for Multiple Sclerosis

Other health conditions supported by Cannabidiol

Products containing Cannabidiol